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A B S T R A C T
Observational epidemiological evidence supports a linear and independent association between serum gamma-
glutamyltransferase (GGT) concentrations and the risk of Alzheimer's disease (AD). However, the causality of
this association has not been previously investigated. We sought to assess the causal nature of this association
using a Mendelian randomization (MR) approach. Using inverse-variance weighted MR analysis, we assessed the
association between GGT and AD using summary statistics for single nucleotide polymorphism (SNP)-AD as-
sociations obtained from the International Genomics of Alzheimer's Project of 17,008 individuals with AD and
37,154 controls. We used 26 SNPs signiﬁcantly associated with GGT in a previous genome-wide association
study on liver enzymes as instruments. Sensitivity analyses to account for potential genetic pleiotropy included
MR-Egger and weighted median MR.
The odds ratio of AD was 1.09 (95% conﬁdence interval, 0.98 to 1.22; p = 0.10) per one standard deviation
genetically elevated GGT based on all 26 SNPs. The results were similar in both MR-Egger and weighted median
MR methods. Overall, our ﬁndings cannot conﬁrm a strong causal eﬀect of GGT on AD risk. Further MR in-
vestigations using individual-level data are warranted to conﬁrm or rule out causality.
1. Introduction
The global prevalence of Alzheimer's disease (AD) is expected to
increase to 106 million in 2050 from 30 million in 2010 (Brookmeyer
et al., 2007), which will further impose a signiﬁcant economic burden
on health systems and society as a whole (Brookmeyer et al., 2007). It
has been reported that one-third of AD cases globally may be attribu-
table to modiﬁable risk factors such as type 2 diabetes, hypertension,
obesity, dyslipidemia, smoking, physical inactivity, smoking, and de-
pression (Peters et al., 2008). Though these factors explain a large
proportion of the risk of AD, its pathogenesis is still not fully established
as the causal eﬀects of these factors on AD risk are uncertain and other
potential risk factors appear to be involved in AD development. There is
therefore a need to critically evaluate putative risk factors that may
have causal signiﬁcance and help prioritize targets for eﬀective pre-
vention and management. Serum gamma-glutamyltransferase (GGT), a
marker of liver injury and excessive alcohol consumption and also
known to have pro-oxidant and pro-inﬂammatory properties (Emdin
et al., 2005); has been linked with an increased risk of several chronic
disease outcomes, including vascular and non-vascular conditions
(Kunutsor et al., 2014a; Kunutsor, 2016; Kunutsor et al., 2015a;
Kunutsor et al., 2015c; Kunutsor et al., 2014c; Kunutsor and Laukkanen,
2016).
In a recent assessment of the prospective association of baseline and
long-term values of GGT with risk of dementia as well as AD in a po-
pulation-based cohort of middle-aged to older Finnish men, we have
demonstrated independent and log-linear associations between GGT
and both outcomes (Kunutsor and Laukkanen, 2016). We reported
multivariate adjusted hazard ratios of 1.33 and 1.24 for dementia and
AD respectively per 1 standard deviation (SD) increase in baseline
serum GGT. On correction for regression dilution, the corresponding
estimates were respectively 1.51 and 1.37 per 1 SD increase in long-
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term serum GGT. In another recent longitudinal study conducted in
older individuals, Praetorius Björk and Johansson demonstrated higher
GGT concentrations to be associated with cognitive decline prior to
death and vascular dementia in late life (Praetorius Bjork and
Johansson, 2017).
It is however unclear whether the association between GGT and AD
is free of unobserved confounding and/or reverse causation (Keavney,
2002; Petitti and Freedman, 2005). In the present study, we aimed to
investigate whether the association between elevated GGT concentra-
tions and increased AD risk is causal, using publicly available data of
genome-wide association studies (GWAS) on liver enzymes and the
International Genomics of Alzheimer's Project (IGAP), which is the
largest genome-wide meta-analysis of AD reported to date (Lambert
et al., 2013).
2. Methods
2.1. Single nucleotide polymorphisms associated with gamma-
glutamyltransferase
Available GWASs reporting on the associations of SNP variants with
serum GGT concentrations at genome-wide signiﬁcant levels
(p < 5×10−8) were included in the present analyses. Studies were
identiﬁed by searching the original publications of GWASs for serum
GGT that have been indexed by the National Human Genome Research
Institute(NHGRI) GWAS catalogue (Hindorﬀ et al., n.d.). The variants
were identiﬁed from a large GWAS on liver enzymes comprising of
61,089 individuals from 21 European countries (Chambers et al., 2011).
Genetic associations were reported as percentage changes in serum GGT
concentrations. These were converted into changes in log-transformed
GGT. We selected the 26 independent SNPs associated with serum GGT
at genome-wide signiﬁcance and which explained 1.9% of the total
variation in serum GGT.
2.2. Data sources
For the present study, we used the publicly available GWAS data of
the IGAP (Lambert et al., 2013), which is a large two-stage study based
upon GWAS on individuals of European ancestry. In stage 1, IGAP used
genotyped and imputed data on 7,055,881 single nucleotide poly-
morphisms (SNPs) to meta-analyse four previously-published GWAS
datasets consisting of 17,008 Alzheimer's disease cases and 37,154
controls (The European Alzheimer's disease Initiative – EADI the Alz-
heimer Disease Genetics Consortium – ADGC The Cohorts for Heart and
Aging Research in Genomic Epidemiology consortium – CHARGE The
Genetic and Environmental Risk in AD consortium – GERAD). In stage
2, 11,632 SNPs were genotyped and tested for association in an in-
dependent set of 8572 Alzheimer's disease cases and 11,312 controls.
Finally, a meta-analysis was performed combining results from stages 1
& 2. We selected the 26 GGT-related SNPs and extracted their eﬀect
estimates for AD (odds ratios, ORs) together with their accompanying
standard errors from IGAP.
2.3. Power calculation
Estimates of power for the MR analysis on AD employed an online
power calculator ([http://cnsgenomics.com/shiny/mRnd/]). We used
the genetic sample size and case/control ratios together with the pro-
portion of variance of GGT explained by the GRS. Using IGAP data,
(Lambert et al., 2013) we had 82% power to detect a causal association
with an OR of ≥1.20 per 1 standard deviation increase in serum GGT.
Fig. 1. Associations of individual genetic variants with GGT and
with Alzheimer's disease.
Results displayed as the additive beta estimates and 95% con-
ﬁdence intervals. Horizontal axis presents the additive (per al-
lele) associations of genetic variants with log-transformed GGT
concentrations. Vertical axis presents the genetic associations
with Alzheimer's disease risk (log odds ratio). The solid line re-
presents the regression line of the inverse-variance weighted
approach to combine the individual genetic variants; GGT,
gamma-glutamyltransferase.
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2.4. Statistical analyses
We used the reported SNP-GGT and SNP-AD association estimates to
calculate a combined eﬀect of the individual 26 SNPs on AD using an
inverse-variance weighted (IVW) approach (Burgess et al., 2013).
Sensitivity analyses involved calculating MR-Egger (Bowden et al.,
2015) and weighted median (Bowden et al., 2016a) estimates, as the
IVW estimates may be biased by inclusion of invalid genetic instru-
mental variables. MR-Egger regression analyses allowed the formal
testing for the presence of directional pleiotropy. The combined eﬀect
of the SNPs is presented as the eﬀect per 1 SD increase in genetically
determined GGT with a 95% conﬁdence interval (CI). A 1 SD increase
was taken as a 0.65 unit increase in log-transformed GGT concentra-
tions (Kunutsor and Laukkanen, 2016), equivalent to a 92% increase in
GGT concentrations. The eﬀect of GGT on AD from observational evi-
dence was compared with the estimate obtained from the genetic
analyses.
3. Results
3.1. Genetic variants for GGT and Alzheimer's disease
Fig. 1 shows the associations of SNPs with GGT concentrations and
AD risk. F-statistics of the individual SNPs ranged from 36.5 to 324.3
and the mean F-statistic of all 26 SNPs was 48.4. We found no evidence
of an association between any of the individual SNPs for GGT and the
risk of AD after accounting for multiple testing (only rs13030978 had
p=0.046, all other SNPs had p > 0.05). Using all the SNPs together in
the IVW method, the causal OR for AD was estimated as 1.09 (95% CI,
0.98 to 1.22) per 1 SD increase in serum GGT concentration (Fig. 2).
MR-Egger regression and weighted median estimators were consistent
with IVW results, [OR 0.89 (0.69 to 1.16), p=0.39] and [OR 1.06
(0.98 to 1.35), p=0.092] respectively. Furthermore, in the MR-Egger
regression analysis, there was no evidence of deviation of the intercept
from zero [0.015, p=0.070] (Table 1), indicating the absence of
pleiotropy in the IVW SNPs and the I2 statistic was 91.7%, suggesting
minimal bias (Bowden et al., 2016b). Fig. 3 shows a funnel plot of the
genetic associations with GGT against the individual causal eﬀect es-
timates for each variant. A visual inspection of the funnel plot suggests
that there is little asymmetry present.
4. Discussion
Given the previously observed association between elevated GGT
concentrations and higher risk of AD, our aim within the present study
was to investigate if the association was causal. Utilizing summary
statistics of large-scale published GWAS, there was no evidence of an
association between genetically determined serum GGT and risk of AD.
These ﬁndings suggest that the observational association between GGT
and AD might not be causal. Gamma-glutamyltransferase has been
linked with the development of several vascular and non-vascular
outcomes (Kunutsor et al., 2014a; Kunutsor et al., 2014b; Kunutsor
et al., 2015c; Kunutsor et al., 2014c; Kunutsor et al., 2015b; Kunutsor
et al., 2014d) and these relationships have been attributed to its pro-
Fig. 2. Causal estimates from individual SNPs and across all var-
iants.
Causal estimates and 95% conﬁdence intervals (CI) based on each
SNP in turn. Estimates represent odds ratios per 1 SD increase in
GGT concentrations. The pooled estimate is from the inverse-var-
iance weighted (IVW) method to combine evidence across the in-
dividual genetic variants; SNP, single-nucleotide polymorphism.
Table 1
Comparison between observational and genetically determined eﬀect of gamma-gluta-
myltransferase on risk of Alzheimer's disease.
Exposure Odds ratio (95% conﬁdence)
Observational association per 1 SD higher GGT
Baseline GGT 1.24 (1.01 to 1.53)
Long-term “usual levels” of GGT 1.37 (1.01 to 1.85)
Genetic estimate per 1 SD higher GGT
Inverse-variance weighted method 1.09 (0.98 to 1.22)
MR-Egger regression method 0.89 (0.69 to 1.16)
Weighted median method 1.06 (0.98 to 1.35)
GGT, gamma-glutamyltransferase; MR, Mendelian randomization; SD, standard devia-
tion; estimates are reported per 1 standard deviation increase in GGT.
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inﬂammatory and pro-oxidant properties (Emdin et al., 2005) as well as
its direct involvement in atheromatous plaque formation (Franzini
et al., 2009; Paolicchi et al., 2004). Gamma-glutamyltransferase may be
linked to dementia or AD via these pathways (Kunutsor and Laukkanen,
2016), given the involvement of these processes in the development of
these neurodegenerative conditions (Breteler, 2000; Gackowski et al.,
2008; McGeer and McGeer, 2013; Yavuz et al., 2008; Zafrilla et al.,
2006). Gamma-glutamyltransferase is also strongly related with meta-
bolic abnormalities such as metabolic syndrome (Kunutsor et al.,
2015b), obesity (Marchesini et al., 2005), and non-alcoholic fatty liver
disease (Angulo, 2002), which are relevant to the development of AD
(Kivimaki et al., 2017; Seo et al., 2016).
Given that the current results do not provide strong evidence for a
causal association between GGT concentrations and AD risk, previous
observational ﬁndings could have been the result of residual con-
founding and/reverse causality (elevated GGT concentrations being a
consequence of the neurodegenerative process). However, the me-
chanisms postulated to link elevated GGT concentrations and increased
AD are biologically plausible. The ﬁndings of a linear and independent
association between GGT concentrations and AD risk in previous ob-
servational cohort studies are also suggestive of causality. Further stu-
dies are therefore needed to investigate this research question.
There are several strengths and weaknesses of the current in-
vestigation which merit consideration. Obviously, the current ﬁndings
are important and less prone to bias than ﬁndings from traditional
observational epidemiological studies, because causal investigations
with the use of genetic variants are likely to be free from confounding,
not subject to reverse-causation, and genetically-elevated serum GGT
concentration is indicative of life-long values. The main data source for
this study is the summary statistics from IGAP, which is the largest
GWAS of AD reported to date (Lambert et al., 2013). Our MR approach
employed the use of summarized publicly available data which pre-
cluded the ability to fully assess instrumental variable assumptions such
as: (i) adequately address population stratiﬁcation; (ii) test for the at-
tenuation of genetic associations with the outcome on adjustment for
the exposure of interest; (iii) test for assumptions required by
instrumental variable methods for eﬀect estimation such as pleiotropy
(Burgess et al., 2013). Also, it was not possible to evaluate the biology
of the GGT variants in detail because of the use of summary statistics
from published studies; therefore there is a possibility that other bio-
logical pathways might explain the associations of some of these var-
iants with GGT. However, it is unlikely that our results were aﬀected by
potential pleiotropy given the results from our MR-Egger-regression
analyses. Our use of multiple SNPs also minimized the risk of pleio-
tropy. Furthermore, the SNP variants selected as instruments were
strongly associated with GGT concentrations and their F-statistics
were>10. A limitation of the MR approach is the limited strength of
the SNPs to explain considerable variation in GGT concentrations,
which may have restricted statistical power. However, the use of a large
number of genetic variants and IGAP data may have provided suﬃcient
power to detect any causal association of GGT with AD. Finally, since
all participants in IGAP and the GWAS of liver enzymes are of European
descent, the current ﬁndings cannot be necessarily generalized to other
ethnic groups.
5. Conclusion
Overall, our ﬁndings cannot conﬁrm any causal eﬀect of GGT on AD
risk. Given the limitations of the present study, further MR investiga-
tions using individual-level data are warranted to conﬁrm or rule out
causality.
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